Education
About Us
Working with TipRanks
Follow Us
Neurosense Therapeutics Ltd. (NRSN)
:NRSN
RESEARCH TOOLSreports
NRSN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $2.60
Previous CloseN/A
Volume34.16K
Average Volume (3M)1.03M
Market Cap
$29.03M
Enterprise Value$24.53M
Total Cash (Recent Filing)$344.00K
Total Debt (Recent Filing)$19.00K
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 26, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding24,602,406
10 Day Avg. Volume2,471,589
30 Day Avg. Volume1,033,635
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$14.00Price Target Upside1086.44% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
ManufacturingNRSN has completed the scale-up of its manufacturing process of PrimeC to commercial scale.
Product DevelopmentNeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS), and previously received feedback from the FDA regarding the Phase trial 3 design for PrimeC.
Bears Say
Financial ConstraintsWhile the data previously generated for PrimeC has been promising, the company still has capital constraints, including its 'baby shelf' limitations, which will make it difficult to raise sufficient capital to fully finance the Phase 3 trial.
Funding UncertaintyNeuroSense still has not signed a definitive agreement with the previously-undisclosed partner to fund PrimeC’s Phase 3 program and commercialization.
Regulatory ChallengesThe company received negative feedback from Health Canada regarding an accelerated approval pathway for PrimeC for treating ALS.
Neurosense Therapeutics Ltd. News
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $0.80 and its highest was $2.60 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Neurosense Therapeutics Ltd.’s market cap is $29.03M.
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Nov 26, 2025 which is in 68 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Aug 01, 2025. The company reported -$0.138 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.085.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate is -0.06.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 24,602,406 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$0.138 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -40%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
Neurosense Therapeutics Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$14.00 (1086.44% Upside)
$14.00 (1086.44% Upside)
Hedge Fund Trend
Decreased
By 19.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.94%
12-Months-Change
Fundamentals
Return on Equity
-2880.11%
Trailing 12-Months
Asset Growth
44.05%
Trailing 12-Months
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NRSN Stock 12 Month Forecast
Average Price Target
$14.00
▲(1086.44% Upside)
Technical Analysis
Ownership Overview
26.88%
Insiders
0.06% Mutual Funds
0.19% Other Institutional Investors
99.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---